93 related articles for article (PubMed ID: 12774471)
1. [Sulfonylurea receptors and their interaction with glimepiride].
Zueva NA; Sologub NV; Efimov AS
Lik Sprava; 2003; (2):35-9. PubMed ID: 12774471
[TBL] [Abstract][Full Text] [Related]
2. [Glimepiride].
Nakamura N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
[No Abstract] [Full Text] [Related]
3. [Sulfonylurea drugs for type 2 diabetes].
Toyota T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
[No Abstract] [Full Text] [Related]
4. [The role of sulphonylurea derivatives in treatment of diabetes type 2. The role of glimepiride].
Sieradzki J
Przegl Lek; 2000; 57 Suppl 4():13-8. PubMed ID: 11293224
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacology of glimepiride].
Satoh Y
Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
[No Abstract] [Full Text] [Related]
6. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
[TBL] [Abstract][Full Text] [Related]
7. Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
Ammälä C; Moorhouse A; Gribble F; Ashfield R; Proks P; Smith PA; Sakura H; Coles B; Ashcroft SJ; Ashcroft FM
Nature; 1996 Feb; 379(6565):545-8. PubMed ID: 8596634
[TBL] [Abstract][Full Text] [Related]
8. [Drugs stimulating insulin release. Importance of their use for improving glycemia, safety and quality of life in diabetes mellitus type 2].
Sieradzki J
Przegl Lek; 2000; 57(1):5-8. PubMed ID: 10907360
[TBL] [Abstract][Full Text] [Related]
9. [A rapid- and short-acting insulinotropic agent KAD-1229].
Komatsu H; Ohnota H; Koizumi T; Satoh F
Nihon Rinsho; 1997 Nov; 55 Suppl():171-9. PubMed ID: 9434463
[No Abstract] [Full Text] [Related]
10. [Molecular basis of oral hypoglycemic sulfonylurea action].
Owecki M; Horst-Sikorska W; Sowiński J
Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
[TBL] [Abstract][Full Text] [Related]
11. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study.
Meirhaeghe A; Helbecque N; Cottel D; Arveiler D; Ruidavets JB; Haas B; Ferrières J; Tauber JP; Bingham A; Amouyel P
Am J Med Genet; 2001 Jun; 101(1):4-8. PubMed ID: 11343328
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
Zychma MJ; Gumprecht J; Strojek K; Grzeszczak W; Moczulski D; Trautsolt W; Karasek D
Med Sci Monit; 2002 Jul; 8(7):CR512-5. PubMed ID: 12118200
[TBL] [Abstract][Full Text] [Related]
13. Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S; Takahashi H; Takahashi T; Shibasaki T
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of the glycaemic effects of sulfonylureas.
Ashcroft FM
Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
[TBL] [Abstract][Full Text] [Related]
15. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Leibowitz G; Cerasi E
Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
[TBL] [Abstract][Full Text] [Related]
16. [Sulfonylurea receptors].
Huupponen R
Duodecim; 1989; 105(19):1578-80. PubMed ID: 2553390
[No Abstract] [Full Text] [Related]
17. A new mesangial triumvirate: sulfonylureas, their receptors and endosulfines.
Yee J; Szamosfalvi B
Exp Nephrol; 2002; 10(1):1-6. PubMed ID: 11803199
[TBL] [Abstract][Full Text] [Related]
18. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics.
Tayek J
Diabetes Obes Metab; 2008 Nov; 10(11):1128-9; author reply 1129-30. PubMed ID: 18671799
[No Abstract] [Full Text] [Related]
19. Genetic cause of hyperglycaemia and response to treatment in diabetes.
Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
[TBL] [Abstract][Full Text] [Related]
20. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
Harrower A
Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
